Longboard Pharmaceuticals (LBPH) to Release Earnings on Thursday

Longboard Pharmaceuticals (NASDAQ:LBPH) is set to release its earnings data after the market closes on Thursday, August 1st. Analysts expect Longboard Pharmaceuticals to post earnings of ($0.46) per share for the quarter.

Longboard Pharmaceuticals (NASDAQ:LBPH) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.06. On average, analysts expect Longboard Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Longboard Pharmaceuticals Stock Down 3.4 %

Shares of NASDAQ LBPH traded down $1.18 during mid-day trading on Tuesday, reaching $33.70. 130,170 shares of the company were exchanged, compared to its average volume of 935,249. Longboard Pharmaceuticals has a 52 week low of $3.60 and a 52 week high of $40.48. The company’s 50 day moving average price is $26.07 and its 200 day moving average price is $22.70. The stock has a market capitalization of $1.31 billion, a PE ratio of -15.57 and a beta of 1.24.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on LBPH shares. Cantor Fitzgerald upped their price objective on Longboard Pharmaceuticals from $60.00 to $90.00 and gave the stock an “overweight” rating in a report on Monday, July 1st. Wedbush increased their price target on shares of Longboard Pharmaceuticals from $32.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Citigroup boosted their price objective on shares of Longboard Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Evercore ISI lifted their target price on shares of Longboard Pharmaceuticals from $57.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Longboard Pharmaceuticals in a research note on Tuesday, June 11th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $54.63.

About Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.